A third-party commentary published on October 18 argues that Guardant Health’s Shield and Reveal data support an “undervalued” thesis. But the supplied headline offers no details about the data or valuation, and it does not point to a new company announcement. Guardant Health shares closed at US$158.60, down 4.39% for the day, according to the supplied figures.
Investor takeaway: The headline makes a valuation claim, but the available facts aren’t enough to assess it.
US$158.60 closing price
Advertisement
Guardant Health Inc
GH.US
GH.US
Guardant Health Inc
WealthAwesomeMarket cap
$21.28B
52W high
$191.05
52W low
$66.59
1W change
-5.30%
Beta
1.58
Analyst Price Targets
Based on 26 analysts covering GH · as of Oct 14, 2026
Wall Street analysts forecast GH stock price to rise 1377.2% over the next 12 months.
Consensus
Strong Buy4.69 / 5.00
Avg. Target
C$201.64
+1377.2% Upside
Previously C$201.04 on Oct 13, 2026
Current Price
C$13.65
Last close
Analyst Breakdown (26 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GH's historical volatility
30-Day Vol
48.1%
Annualized
90-Day Vol
50.8%
Annualized
Trend (90d)
+22.9%
Annualized drift
90d Mean
C$172.09
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$162.97 | C$138.05 – C$192.39 |
| 60 trading days | C$167.47 | C$132.44 – C$211.77 |
| 90 trading days | C$172.09 | C$129.10 – C$229.39 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Guardant Health closed at US$158.60, down 4.39% for the day and 9.32% over the past month. The shares were up 55.89% year to date.
Bull case
The commentary cites Shield and Reveal data in support of its undervaluation argument. The share price also remains above its 200-day moving average.
Bear case
The headline provides no details about the data or the valuation method. Guardant Health also reported a negative profit margin and negative trailing-twelve-month EPS in the supplied figures.
What the Shield and Reveal headline says
The October 18 item is third-party commentary, not a company filing or announcement in the supplied facts. Its headline says Guardant Health’s Shield and Reveal data support an “undervalued” thesis. But the available information doesn’t describe the data, say when it was generated, or explain the valuation method. So the headline is an opinion, not evidence that the company is undervalued. See the GH.US stock page for the supplied market information.
The supplied market figures
Advertisement
Guardant Health’s last close was US$158.60. Shares fell 4.39% in one day, 5.30% in one week and 9.32% in one month. They were up 55.89% year to date.
The close was 5.6% below the 50-day moving average of US$168.08 and 24.6% above the 200-day average of US$127.26. The supplied latest volume was 3,282 shares, compared with a 20-day average of 1,874,192. The reported volume ratio was 1.05x. The figures don’t explain the difference between the volume numbers, so they don’t establish how investors responded to the commentary.
Market capitalization was about US$21.3 billion. The reported profit margin was -38.3%, and trailing-twelve-month EPS was -US$3.50.
What to watch next
The main question is which Shield and Reveal data the commentary cites and how they support its valuation claim. The supplied facts include no new clinical results, company guidance or filing tied to the October 18 headline.
A separate October 17 headline mentions a patent setback, but the available facts provide no details, so its implications are unclear. More company disclosures or fuller details behind the commentary would help clarify the claims. Investors can also check the GH.US analyst-ratings page for the supplied analyst information, though it doesn’t establish the commentary’s valuation case.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
